Company Encyclopedia
View More
name
Absci
ABSI.US
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its preclinical development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc.
1.871 T
ABSI.USMarket value -Rank by Market Cap -/-

Financial Score

19/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking228/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-55.68%E
    • Profit Margin-4071.19%E
    • Gross Margin-4992.33%E
  • Growth ScoreD
    • Revenue YoY-33.09%E
    • Net Profit YoY-17.34%D
    • Total Assets YoY4.15%C
    • Net Assets YoY4.47%C
  • Cash ScoreD
    • Cash Flow Margin-2.46%D
    • OCF YoY-33.09%E
  • Operating ScoreE
    • Turnover0.01E
  • Debt ScoreA
    • Gearing Ratio14.14%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    AbSci’s ABS-201: Promising AGA Treatment with Key Milestones Ahead

    H.C. Wainwright analyst Swayampakula Ramakanth maintains a Buy rating on AbSci's stock, citing the potential of its ABS-201 program for treating androgenetic alopecia. The program shows promising preclinical results and upcoming milestones, including a proof-of-concept readout in 2026. Ramakanth, a 5-star analyst, sees the stock as a compelling buy due to anticipated clinical milestones and current valuation. Needham also maintains a Buy rating with a $7.00 price target.

    Tip Ranks·
    US
    ABSI
    +0.59%
    Tip Ranks·
    US
    ABSI
    +0.59%

    Absci Corporation to Present at J.P. Morgan Healthcare Conference

    Absci Corporation will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14th, 2025, at 3:45 p.m. Pacific Time. The announcement was originally published by Absci Corporation via GlobeNewswire.

    Reuters·
    US
    ABSI
    +0.59%
    Reuters·
    US
    ABSI
    +0.59%

    Promising Prospects for AbSci’s ABS-201 in Androgenetic Alopecia: Buy Rating Affirmed

    Needham's Gil Blum maintains a Buy rating on AbSci with a $7 target, citing promising preclinical results for ABS-201 in androgenetic alopecia. The drug shows a unique mechanism and potential market interest, with clinical proof expected by 2026. JonesTrading also supports a Buy rating with a $9 target.

    Tip Ranks·
    US
    ABSI
    +0.59%
    Tip Ranks·
    US
    ABSI
    +0.59%

    Absci Unveils AI-Designed Antibody That Stimulates Human Hair Growth

    Absci Corporation has unveiled preclinical data showing its AI-designed antibody, ABS-201, stimulates hair growth in human scalp models. ABS-201 targets the prolactin receptor, promoting hair follicle regeneration and potentially treating androgenetic alopecia. Findings were presented at Absci’s seminar, with detailed results available on their investor relations website. This AI-generated news brief is for informational purposes only and not financial advice.

    Reuters·
    US
    ABSI
    +0.59%
    Reuters·
    US
    ABSI
    +0.59%

    Dir Van Houten Buys 40,000 ($148.8K) Of AbSci Corp [ABSI]

    Van Houten Frans Director of AbSci Corp [ABSI] filed a Form 4 on December 9, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/5/25TransactionPurchaseShares40,000Price$3.72Value$148,800Ending Holdings: 63,320 - DirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    ABSI
    +0.59%
    Reuters·
    US
    ABSI
    +0.59%
    © 2025 Longbridge｜Disclaimer